Zobrazeno 1 - 10
of 5 493
pro vyhledávání: '"Palbociclib"'
Autor:
Takayuki Kobayashi, Meiko Nishimura, Mari Hosonaga, Rika Kizawa, Saori Kawai, Yosuke Aoyama, Yukinori Ozaki, Ippei Fukada, Fumikata Hara, Toshimi Takano, Takayuki Ueno
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Absolute lymphocyte count (ALC) is a predictive and prognostic factor for various tumor types, including breast cancer. Palbociclib is a CDK4/6 inhibitor widely used for the treatment of metastatic estrogen receptor (ER)-positive,
Externí odkaz:
https://doaj.org/article/1e6f7c53792d4145b42f0e111048dcb5
Autor:
Rand K. Jadallah, Ahmed H. Al Sharie, Saja M. Alzghoul, Jawad M. Al-Karaki, Mohammad S. Bani Amer, Tariq H. Rawashdeh, Osama Alshari
Publikováno v:
Radiology Case Reports, Vol 19, Iss 9, Pp 4049-4054 (2024)
The management of advanced metastasized breast cancer (BC) is a clinically challenging entity with a wide spectrum of novel therapeutics being introduced to the market. Such agents have remodeled BC treatment landscape and prolonged patients’ survi
Externí odkaz:
https://doaj.org/article/d6dc1c8484a142c78d3ebc441ef26a5b
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 395-418 (2024)
Abstract Introduction Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain
Externí odkaz:
https://doaj.org/article/d3d5c5d38dd54e5fb401805a467c3fba
Autor:
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhib
Externí odkaz:
https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Hepatocellular carcinoma (HCC) poses a significant clinical challenge, necessitating the integration of immunotherapeutic approaches. Palbociclib, a selective CDK4/6 inhibitor, has demonstrated promising efficacy in preclinical HCC models an
Externí odkaz:
https://doaj.org/article/98910cd9e30942b5a5cfac1927fa60df
Autor:
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Marika Di Dio, Azzurra Zicarelli, Salvatore De Rosis, Anna Maria Miglietta, Carlo Capalbo, Ernestina Marianna De Francesco, Antonino Belfiore, Fedora Grande, Bruno Rizzuti, Maria Antonietta Occhiuzzi, Giancarlo Fortino, Antonella Guzzo, Gianluigi Greco, Marcello Maggiolini, Rosamaria Lappano
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-22 (2024)
Abstract Background The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (B
Externí odkaz:
https://doaj.org/article/953c860ef51d47f89a770236fa68ff4a
Autor:
Imtiaz A Samjoo, Alexandra Hall, Connie Chen, Bao-Ngoc Nguye, Meaghan Bartlett, Mary Lou Smith, Nadia Harbeck, Joseph C Cappelleri, Meghan Karuturi, Doris Makari, Lillian Shahied Arruda, Rickard Sandin, Kent Hanson, Justin Doan
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast cancer (
Externí odkaz:
https://doaj.org/article/f6f1b3a08af445aab4c5bd48f8bb6817
Autor:
Elena Peruzzi, Bianca Posocco, Lorenzo Gerratana, Margherita Nuti, Marco Orleni, Sara Gagno, Elena De Mattia, Fabio Puglisi, Erika Cecchin, Giuseppe Toffoli, Rossana Roncato
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the influence of diverse clinical and biological factors—age, renal function, genetic variations,
Externí odkaz:
https://doaj.org/article/b521bc612660403e8b9680b8ad7af635
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer. This article aim
Externí odkaz:
https://doaj.org/article/677acbb956ea4a74afd45acba5093f15